Left lateral segment pediatric liver transplantation: a 25 year experience at Mount Sinai.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
06 2022
Historique:
received: 27 04 2021
revised: 08 08 2021
accepted: 30 09 2021
pubmed: 8 11 2021
medline: 7 6 2022
entrez: 7 11 2021
Statut: ppublish

Résumé

Outcomes of left lateral segment (LLS) grafts in pediatric recipients were compared between living (LD-LLS) and deceased donor (DD-LLS) grafts. 195 LLS grafts (99DD-LLS-96LD-LLS) were analyzed with a median follow-up of 9.1years. The primary endpoints were overall patient/graft survival. LD-LLS grafts were younger (0.9vs.1.4years, p = 0.039), more likely to have a fulminant liver failure (17.9%vs.5.3%,p = 0.002), less likely to have a metabolic disorder (6.3%vs.25.5%,p = 0.002), and less likely to be undergoing retransplantation (5.3% vs.16.2%,p = 0.015). There was a trend toward decreased hepatic artery thrombosis in LD-LLS grafts (6.6% vs. 15.5%,p = 0.054). No differences in the overall biliary complications occurred. The LD-LLS group had prolonged survival compared to the DD-LLS group with 10-year survival rates of 81%, and 74% (p = 0.005), respectively. LD-LLS grafts had longer graft survival compared to DD-LLS grafts (10-year graft survival 85%vs.67%,p = 0.005). Recipient age >1year (HR 2.39,p = 0.026), aortic reconstruction (HR 2.12,p = 0.046) and vascular complication (HR 3.12,p < 0.001) were independent predictors of poor patient survival. Non-biliary liver disease (HR 2.17,p = 0.015), DD-LLS (HR 2.06,p = 0.034) and vascular complication (HR 4.61,p < 0.001) were independent predictors of poor graft survival. The use of SLT remains a viable option with excellent long-term outcomes. We show improved graft and patient survival with living donor grafts.

Sections du résumé

BACKGROUND
Outcomes of left lateral segment (LLS) grafts in pediatric recipients were compared between living (LD-LLS) and deceased donor (DD-LLS) grafts.
METHODS
195 LLS grafts (99DD-LLS-96LD-LLS) were analyzed with a median follow-up of 9.1years. The primary endpoints were overall patient/graft survival.
RESULTS
LD-LLS grafts were younger (0.9vs.1.4years, p = 0.039), more likely to have a fulminant liver failure (17.9%vs.5.3%,p = 0.002), less likely to have a metabolic disorder (6.3%vs.25.5%,p = 0.002), and less likely to be undergoing retransplantation (5.3% vs.16.2%,p = 0.015). There was a trend toward decreased hepatic artery thrombosis in LD-LLS grafts (6.6% vs. 15.5%,p = 0.054). No differences in the overall biliary complications occurred. The LD-LLS group had prolonged survival compared to the DD-LLS group with 10-year survival rates of 81%, and 74% (p = 0.005), respectively. LD-LLS grafts had longer graft survival compared to DD-LLS grafts (10-year graft survival 85%vs.67%,p = 0.005). Recipient age >1year (HR 2.39,p = 0.026), aortic reconstruction (HR 2.12,p = 0.046) and vascular complication (HR 3.12,p < 0.001) were independent predictors of poor patient survival. Non-biliary liver disease (HR 2.17,p = 0.015), DD-LLS (HR 2.06,p = 0.034) and vascular complication (HR 4.61,p < 0.001) were independent predictors of poor graft survival.
CONCLUSION
The use of SLT remains a viable option with excellent long-term outcomes. We show improved graft and patient survival with living donor grafts.

Identifiants

pubmed: 34742650
pii: S1365-182X(21)01659-2
doi: 10.1016/j.hpb.2021.09.024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

817-824

Informations de copyright

Copyright © 2021 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Auteurs

Parissa Tabrizian (P)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA. Electronic address: Parissa.tabrizian@mountsinai.org.

Matthew L Holzner (ML)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Dylan Adamson (D)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Deniz Balci (D)

Department of Surgery and Liver Transplantation Unit, Ankara University School of Medicine, Ankara, Turkey.

Yun K Jung (YK)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Ronen Arnon (R)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Jaime Chu (J)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Sukru Emre (S)

Department of Surgery, Section of Transplantation, Yale University School of Medicine, New Haven, CT, USA.

Marcelo Facciuto (M)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Myron Schwartz (M)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Jang Moon (J)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Kishore Iyer (K)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Sander Florman (S)

Recanati/Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH